Pliant Therapeutics, Inc.
PLRX
$1.38
-$0.09-6.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 0.00 | 248.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 0.00 | 248.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 0.00 | 0.00 | 248.00K |
| SG&A Expenses | 59.31M | 59.06M | 58.38M | 59.47M | 59.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 234.91M | 228.37M | 222.08M | 207.75M | 194.69M |
| Operating Income | -234.91M | -228.37M | -222.08M | -207.75M | -194.44M |
| Income Before Tax | -219.52M | -210.30M | -201.68M | -185.41M | -170.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -219.52 | -210.30 | -201.68 | -185.41 | -170.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -219.52M | -210.30M | -201.68M | -185.41M | -170.74M |
| EBIT | -234.91M | -228.37M | -222.08M | -207.75M | -194.44M |
| EBITDA | -232.85M | -226.24M | -219.95M | -205.71M | -192.54M |
| EPS Basic | -3.61 | -3.47 | -3.34 | -3.09 | -2.86 |
| Normalized Basic EPS | -2.26 | -2.17 | -2.09 | -1.93 | -1.79 |
| EPS Diluted | -3.61 | -3.47 | -3.34 | -3.09 | -2.86 |
| Normalized Diluted EPS | -2.26 | -2.17 | -2.09 | -1.93 | -1.79 |
| Average Basic Shares Outstanding | 243.19M | 242.15M | 241.20M | 240.16M | 238.95M |
| Average Diluted Shares Outstanding | 243.19M | 242.15M | 241.20M | 240.16M | 238.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |